Trifluridine/Tipiracil Based Chemoradiation in locally Advanced Rectal Cancer: The Phase I/II TARC Trial
Clinical Colorectal Cancer · 2025
DOI: 10.1016/j.clcc.2024.06.003 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical Colorectal Cancer, 2025. Verfasst von Benjamin Thiele und 14 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, University Hospital Basel, Basel, Switzerland; Laboratory of Translational Immuno-Oncology, Department of Biomedicine, University a…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Chemoradiotherapy, Circulating Tumor DNA, Rectal Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Hamburg-Eppendorf, Les Laboratoires Servier Canada Inc.
Abstract (Originalsprache)
BACKGROUND: Optimizing functional outcomes and securing long-term remissions are key goals in managing patients with locally advanced rectal cancer. In this proof-of-concept study, we set out to further optimize neoadjuvant therapy by integrating the radiosensitizer trifluridine/tipiracil and explore the potential of cell free tumor DNA (ctDNA) to monitor residual disease. METHODS: About 10 patients were enrolled in the phase I dose finding part which followed a 3 + 3 dose escalation design. Tipiracil/trifluridine was administered concomitantly to radiotherapy. ctDNA monitoring was performed before and after chemoradiation with patient-individualized digital droplet PCRs. RESULTS: No dose-limiting toxicities were observed at the maximum tolerated dose level of 2 × 35 mg/m² trifluridine/tipiracil. There were 9 grade 3 adverse events, of which 8 were hematologic with anemia and leukopenia. Chemoradiation yielded a pathological complete response in 1 out of 8 assessable patients, downstaging in nearly all patients, and 1 clinical complete response referred for watchful waiting. Three of 4 assessable patients with residual tumor cells at pathological assessment remained liquid biopsy positive after chemoradiation, but 1 turned negative. CONCLUSION: In this exploratory phase I trial, the novel combination of neoadjuvant trifluridine/tipiracil and radiotherapy proved to be feasible, tolerable, and effective. However, the application of liquid biopsy as a potential marker for therapeutic de-escalation in the neoadjuvant setting requires additional research and prospective validation. The trial was registered at ClinicalTrials.gov: NCT04177602.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology, University Hospital Basel, Basel, Switzerland; Laboratory of Translational Immuno-Oncology, Department of Biomedicine, University and University Hospital Basel, Basel, Switzerland.
- Hematology-Oncology Practice Eppendorf (HOPE), Hamburg, Germany; University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: stein@hope-hamburg.de.
- Internal Medicine IV - Oncology/Hematology, University Hospital, Martin-Luther University, Halle, Germany.
- Hematology-Oncology Practice Eppendorf (HOPE), Hamburg, Germany; University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Hämatologisch- Onkologische Praxis Altona, Hamburg, Germany.
- Überörtliche Gemeinschaftspraxis für Innere Medizin Schwerpunkt Hämatologie, Onkologie und Palliativmedizin, Hamburg, Germany.
Förderung
- Universitätsklinikum Hamburg-Eppendorf
- Les Laboratoires Servier Canada Inc
Zitieren
APA
Thiele, B., Stein, A., Schultheiß, C., Paschold, L., Jonas, H., Goekkurt, E., Rüssel, J., Schuch, G., Wierecky, J., Sinn, M., Tintelnot, J., Petersen, C., Rothkamm, K., Vettorazzi, E., & Binder, M. (2025). Trifluridine/Tipiracil Based Chemoradiation in locally Advanced Rectal Cancer: The Phase I/II TARC Trial. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2024.06.003
Vancouver
Thiele B, Stein A, Schultheiß C, Paschold L, Jonas H, Goekkurt E, et al. Trifluridine/Tipiracil Based Chemoradiation in locally Advanced Rectal Cancer: The Phase I/II TARC Trial. Clinical Colorectal Cancer. 2025. doi:10.1016/j.clcc.2024.06.003
BibTeX
@article{Thiele2025,
author = {Thiele, Benjamin and Stein, Alexander and Schultheiß, Christoph and Paschold, Lisa and Jonas, Hanna and Goekkurt, Eray and Rüssel, Jörn and Schuch, Gunter and Wierecky, Jan and Sinn, Marianne and Tintelnot, Joseph and Petersen, Cordula and Rothkamm, Kai and Vettorazzi, Eik and Binder, Mascha},
title = {Trifluridine/Tipiracil Based Chemoradiation in locally Advanced Rectal Cancer: The Phase I/II TARC Trial},
journal = {Clinical Colorectal Cancer},
year = {2025},
doi = {10.1016/j.clcc.2024.06.003}
}
EUVIMED